Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference

NOVATO, Calif., June 10, 2016 -- (Healthcare Sales & Marketing Network) -- Raptor Pharmaceutical Corp. (RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its ... BiopharmaceuticalsRaptor Pharmaceutical, QUINSAIR, Cystic Fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news